Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from its latest cancer treatment study at the world’s largest hematology…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023 which it says has set the stage for a pivotal…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual conference of the International Society of Cell & Gene Therapy…

A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity…

At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination…

Prescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer centre in US to create “best-in-class” adaptable CAR-T cell therapies to treat blood…

Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum in developing its pipeline of innovative cancer and cell therapies…

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a high-performance platform known as CellPryme-M which is designed to enhance…